Akebia Q3 net income $0.5M; Vafseo revenue $14.3M; DaVita pilot ongoing

Akebia Therapeutics, Inc.

2025-Q3 EPS reported $0.03 revenue$178,574,000

Q3 total revenue $58.8M (up 57% YoY vs $37.4M); net income $0.5M vs net loss $20.0M in Q3 2024.
Vafseo net product revenue $14.3M (launched Jan 2025); Auryxia net revenue $42.5M (up from $35.6M).
DaVita operational pilot started Aug 18 over 100 clinics, expected to complete in Q4; target 275K patient access by year-end.
FDA Type C meeting: no alignment on Phase 3 for non-dialysis; Akebia will not pursue broad label for non-dialysis.
Cash $166.4M; company believes financed to achieve profitability under current operating plan.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.